Cargando…

Phase 1 Study Evaluating the Association of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib and Cetuximab in Recurrent/Metastatic p16-Negative Squamous Cell Carcinoma of the Head and Neck

Background: The majority of human papillomavirus (HPV)-negative squamous cell carcinoma of the head and neck (SCCHN) present upregulation of the epidermal growth factor receptor (EGFR) and frequent alterations in the cyclin D1-cyclin dependent kinase (CDK) 4/6 (CDK 4/6)-retinoblastoma protein (pRb)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seront, Emmanuel, Schmitz, Sandra, Papier, Matthias, van Maanen, Aline, Henry, Stéphanie, Lonchay, Christophe, Rottey, Sylvie, van Caloen, Gabrielle, Machiels, Jean-Pascal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6433958/ https://www.ncbi.nlm.nih.gov/pubmed/30941307 http://dx.doi.org/10.3389/fonc.2019.00155

Ejemplares similares

Preclinical Evaluation of the Association of the Cyclin-Dependent Kinase 4/6 Inhibitor, Ribociclib, and Cetuximab in Squamous Cell Carcinoma of the Head and Neck
por: van Caloen, Gabrielle, et al.
Publicado: (2021)

Randomized Phase II Study of Cabazitaxel Versus Methotrexate in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With Platinum-Based Therapy
por: Machiels, Jean-Pascal, et al.
Publicado: (2016)

Dynamic contrast-enhanced computed tomography to assess early activity of cetuximab in squamous cell carcinoma of the head and neck
por: Schmitz, Sandra, et al.
Publicado: (2015)

Cetuximab promotes epithelial to mesenchymal transition and cancer associated fibroblasts in patients with head and neck cancer
por: Schmitz, Sandra, et al.
Publicado: (2015)

Advances in the management of squamous cell carcinoma of the head and neck
por: Machiels, Jean-Pascal, et al.
Publicado: (2014)

Safety and efficacy of cyclin-dependent kinase inhibitor rechallenge following ribociclib-induced limiting hypertransaminasemia
por: Fuentes-Antrás, Jesús, et al.
Publicado: (2020)

Review of cetuximab in the treatment of squamous cell carcinoma of the head and neck
por: Merlano, Marco, et al.
Publicado: (2007)

2′-deoxy-2′-[18F] fluoro-D-glucose positron emission tomography, diffusion-weighted magnetic resonance imaging, and choline spectroscopy to predict the activity of cetuximab in tumor xenografts derived from patients with squamous cell carcinoma of the head and neck
por: Mignion, Lionel, et al.
Publicado: (2018)

Biological Effects of Cyclin-Dependent Kinase Inhibitors Ribociclib, Palbociclib and Abemaciclib on Breast Cancer Bone Microenvironment
por: Iuliani, Michele, et al.
Publicado: (2022)

Cetuximab Rechallenge and Monotherapy in Patients with Squamous Cell Carcinoma of the Head and Neck
por: Knutzen, Greg, et al.
Publicado: (2015)

Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma
por: Leblanc, Olivia, et al.
Publicado: (2020)

Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck
por: Mesía, R., et al.
Publicado: (2010)

Vaccine-Based Immunotherapy for Head and Neck Cancers
por: Beyaert, Simon, et al.
Publicado: (2021)

Recent results of cetuximab use in the treatment of squamous cell carcinoma of the head and neck
por: Perri, Francesco, et al.
Publicado: (2009)

Efficacy of gemcitabine and cetuximab combination treatment in head and neck squamous cell carcinoma
por: MASEKI, SHINICHIRO, et al.
Publicado: (2013)

Inhibition of the CDK4/6-Cyclin D-Rb Pathway by Ribociclib Augments Chemotherapy and Immunotherapy in Renal Cell Carcinoma
por: Chen, Dehong, et al.
Publicado: (2020)

Immuno-Oncological Biomarkers for Squamous Cell Cancer of the Head and Neck: Current State of the Art and Future Perspectives
por: De Keukeleire, Stijn J., et al.
Publicado: (2021)

Aurora Kinase Inhibition Overcomes Cetuximab Resistance in Squamous Cell Cancer of the Head and Neck
por: Hoellein, Alexander, et al.
Publicado: (2011)

Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study
por: Licitra, L., et al.
Publicado: (2011)

Ribociclib Induced Photosensitive Skin Lesions
por: Verma, Vaishnavi, et al.
Publicado: (2022)

Combination of Ribociclib and Gemcitabine for the Treatment of Medulloblastoma
por: Pribnow, Allison, et al.
Publicado: (2022)

Cost-Effectiveness of Cetuximab for Advanced Esophageal Squamous Cell Carcinoma
por: Janmaat, Vincent T., et al.
Publicado: (2016)

Effects of Cetuximab and Erlotinib on the behaviour of cancer stem cells in head and neck squamous cell carcinoma
por: Setúbal Destro Rodrigues, Maria Fernanda, et al.
Publicado: (2018)

Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck
por: Trieu, Vanessa, et al.
Publicado: (2018)

Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
por: Taberna, Miren, et al.
Publicado: (2019)

Cetuximab-induced natural killer cell cytotoxicity in head and neck squamous cell carcinoma cell lines: investigation of the role of cetuximab sensitivity and HPV status
por: Baysal, Hasan, et al.
Publicado: (2020)

Recent advances of cyclin-dependent kinases as potential therapeutic targets in HR+/HER2− metastatic breast cancer: a focus on ribociclib
por: Edessa, Dumessa, et al.
Publicado: (2017)

Characterization of the Synergistic Inhibition of I(K(erg)) and I(K(DR)) by Ribociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor
por: Liu, Pin-Yen, et al.
Publicado: (2020)

Feasibility of Induction Docetaxel, Cisplatin, 5-Fluorouracil, Cetuximab (TPF-C) Followed by Concurrent Cetuximab Radiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma
por: Charalambakis, Nikolaos, et al.
Publicado: (2013)

p16, HPV, and Cetuximab: What Is the Evidence?
por: Bonner, James A., et al.
Publicado: (2017)

A randomized phase II study comparing the efficacy and safety of the glyco-optimized anti-EGFR antibody tomuzotuximab against cetuximab in patients with recurrent and/or metastatic squamous cell cancer of the head and neck – the RESGEX study
por: Klinghammer, K., et al.
Publicado: (2021)

EGFR Monoclonal Antibodies in the Treatment of Squamous Cell Carcinoma of the Head and Neck: A View beyond Cetuximab
por: Kono, Scott A., et al.
Publicado: (2012)

Induction chemotherapy with cetuximab, carboplatin and paclitaxel for the treatment of locally advanced squamous cell carcinoma of the head and neck
por: BAUMAN, JESSICA, et al.
Publicado: (2013)

The response of head and neck squamous cell carcinoma to cetuximab treatment depends on Aurora kinase A polymorphism
por: Pickhard, Anja, et al.
Publicado: (2014)

Cisplatin, Cetuximab, and Radiation in Locally Advanced Head and Neck Squamous Cell Cancer: A Retrospective Review
por: Peddi, Prakash, et al.
Publicado: (2015)

Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma
por: Espinosa-Cotton, Madelyn, et al.
Publicado: (2019)

Predictive Value of Cetuximab-Induced Skin Toxicity in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NECK
por: Uozumi, Shinya, et al.
Publicado: (2018)

Expression of the chemokine CXCL14 and cetuximab-dependent tumour suppression in head and neck squamous cell carcinoma
por: Kondo, T, et al.
Publicado: (2016)

FOXD1 Regulates the Sensitivity of Cetuximab by Regulating the Expression of EGFR in Head and Neck Squamous Cell Cancer
por: Mu, Lan, et al.
Publicado: (2022)

EGFR Inhibition by Cetuximab Modulates Hypoxia and IFN Response Genes in Head and Neck Squamous Cell Carcinoma
por: Chaudhary, Ritu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9favodvpckv9jh4jnok1d11rr3